Ariad Pharmaceuticals Inc fka ARIA

[vidpok45]

It has been apparent for a long time that ponatinib would eventually be the first choice for 2nd line. It is really too bad that even though adjusting the dosage to a more tolerable level (30 to start then 15 to maintain) probably will not ever result in 1st line use only because of the bad reputation due to the excessively high dosage in the trials. Had the trials been run more carefully as a large BP would have done, Ponatinib would already be the 2nd line DOC with a strong possibility of 1st line use which again I think is impossible now only because of its rep. Still, 2nd line use is a billion dollar market and obviously will be factored in for buyout purposes. All good from here on out.